词条 | MorphoSys |
释义 |
| name = MorphoSys AG | logo = Morphosys-logo.svg | logo_size = 230px | type = Aktiengesellschaft | traded_as = {{ubl|{{FWB|MOR}}|{{NASDAQ|MOR}}}} | foundation = {{Start date|1992}} | location = Martinsried, Germany | locations = | area_served = | key_people = Simon Moroney (founder and CEO), Gerald Möller (Chairman of the supervisory board) | industry = Biotechnology | products = Antibodies | services = | revenue = €87.0 million (2010)[1] | operating_income = €9.8 million (2010)[1] | net_income = €9.2 million (2010)[1] | assets = €212.6 million (end 2010)[1] | equity = €185.9 million (end 2010)[1] | num_employees = 460 (end 2010)[1] | divisions = | subsid = | homepage = www.morphosys.com }} MorphoSys AG is a therapeutic antibody company based in Martinsried, Germany. The company claims to have more than 100 drugs in its wider pipeline[2], being investigated for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also maintains an internal pipeline with antibodies in preclinical and clinical development. In July 2017, the first of its platform drugs received FDA approval for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union and Canada. Known as guselkumab (brand name Tremfya), it was developed by Janssen Biotech a subsidiary of Johnson & Johnson. In 2014, MorphoSys joined the TecDAX index, trading on the Frankfurt Stock Exchange under the ticker symbol "MOR." In April 2018, following a U.S. initial public offering, American Depositary Shares of MorphoSys began trading on the Nasdaq, also under the symbol "MOR."[3] As of September 2018, the company had a market capitalization of $3.61 billion.[4] TechnologyMorphoSys generates human antibodies that contain 100% human proteins.[5] The company has named this technology 'HuCal' (Human Combinatorial Antibody Library), and is an antibody production method based on phage display. Patent dispute with Cambridge Antibody TechnologyBoth MorphoSys and Cambridge Antibody Technology based their therapeutic antibody discovery technologies on phage display. Due to the significant CAT patent estate the two came together from 1999 to 2002 in a number of patent disputes that were eventually settled.[6] Timeline of disputes:
The companies agreed to terms under which MorphoSys will be free to develop and commercialise its HuCAL technologies. CAT undertook not to sue MorphoSys in relation to present HuCAL GOLD libraries and all future derivatives thereof. In addition, MorphoSys received a licence to the CAT patent estate in respect of previous HuCAL libraries. CAT received an annual payment of € 1 million over the next five years. It was to also receive other financial consideration from MorphoSys’ activities related to its HuCAL GOLD libraries for a defined period of time. CAT would receive milestone and royalty payments under the licence for products developed using previous HuCAL libraries. In addition, CAT would receive an equity stake of 588,160 ordinary shares in MorphoSys under the licence agreement. MorphoSys retained the option to buy out its obligations to CAT for a pre-defined fixed amount at any time during the duration of the agreement.[16] HistoryIn January 2013, Bio-Rad purchased [https://www.bio-rad-antibodies.com AbD Serotec], a division of MorphoSys AG that sold antibodies.[17] PipelineMorphoSys has numerous candidates in its clinical development pipeline.[18] As of October 2012, its most advanced drug candidate is MOR103, a fully human HuCAL antibody directed against GM-CSF (granulocyte macrophage-colony stimulating factor), developed in the area of inflammatory diseases, i.e. rheumatoid arthritis.[19] References1. ^1 2 3 4 5 {{cite web |url=http://www.morphosys.com/sites/default/files/MOR_Annual_Report_2010.pdf |title=Annual Report 2010 |accessdate=27 March 2010 |publisher=MorphoSys}} 2. ^{{Cite news|url=http://www.ddn-news.com/index.php?newsarticle=9973|title= MorphoSys and Immatics ally in immuno-oncology field|website=Drug Discovery News|access-date=2018-12-13}} 3. ^{{Cite news|url=http://www.bioworld.com/content/morphosys-grosses-208m-nasdaq-listing-0|title=Morphosys grosses $208M in Nasdaq listing|date=2018-04-23|website=BioWorld|access-date=2018-12-13}} 4. ^{{cite web|url=https://bciq.biocentury.com/companies/morphosys_ag|title=Morphosys AG|website=BioCentury|accessdate=2018-12-13}} 5. ^{{cite web |url=http://www.morphosys.com/en/technologies/advantages_of_human_antibodies-130.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20090623031738/http://www.morphosys.com/en/technologies/advantages_of_human_antibodies-130.html |archivedate=2009-06-23 |df= }} 6. ^{{cite web |url=http://www.morphosys.com/en/company/history-85.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20090714050949/http://www.morphosys.com/en/company/history-85.html |archivedate=2009-07-14 |df= }} 7. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-209.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209021321/http://www.morphosys.com/en/news_investors/press-release-209.html |archivedate=2006-12-09 |df= }} 8. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-208.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209021158/http://www.morphosys.com/en/news_investors/press-release-208.html |archivedate=2006-12-09 |df= }} 9. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-167.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209013530/http://www.morphosys.com/en/news_investors/press-release-167.html |archivedate=2006-12-09 |df= }} 10. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-166.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209014039/http://www.morphosys.com/en/news_investors/press-release-166.html |archivedate=2006-12-09 |df= }} 11. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-164.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209013201/http://www.morphosys.com/en/news_investors/press-release-164.html |archivedate=2006-12-09 |df= }} 12. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-163.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209014113/http://www.morphosys.com/en/news_investors/press-release-163.html |archivedate=2006-12-09 |df= }} 13. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-162.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209013016/http://www.morphosys.com/en/news_investors/press-release-162.html |archivedate=2006-12-09 |df= }} 14. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-135.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209011401/http://www.morphosys.com/en/news_investors/press-release-135.html |archivedate=2006-12-09 |df= }} 15. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-134.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20061209011115/http://www.morphosys.com/en/news_investors/press-release-134.html |archivedate=2006-12-09 |df= }} 16. ^{{cite web |url=http://www.morphosys.com/en/news_investors/press-release-132.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20070713155031/http://www.morphosys.com/en/news_investors/press-release-132.html |archivedate=2007-07-13 |df= }} 17. ^{{cite news|title=Bio-Rad Acquires AbD Serotec from MorphoSys|url=http://www.genengnews.com/gen-news-highlights/bio-rad-acquires-abd-serotec-from-morphosys/81247777/|date=17 December 2012}} 18. ^{{cite web |url=http://www.morphosys.com/en/therapeutic_antibodies/overview-446.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20090703095812/http://www.morphosys.com/en/therapeutic_antibodies/overview-446.html |archivedate=2009-07-03 |df= }} 19. ^{{cite web |url=http://www.morphosys.com/en/therapeutic_antibodies/proprietary_therapeutic_product_pipeline-317.html |title=Archived copy |accessdate=2009-08-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20091129133144/http://www.morphosys.com/en/therapeutic_antibodies/proprietary_therapeutic_product_pipeline-317.html |archivedate=2009-11-29 |df= }} External links
3 : Biotechnology companies of Germany|Biotechnology companies established in 1992|1992 establishments in Germany |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。